FDA Drug recall D-264-2013
Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 11…
- FDA Drug
- Class III
- terminated
- Published 2013-04-24
On 2013-04-24 the FDA classified a Class III recall of Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 11… by Lupin Pharmaceuticals, citing discoloration; Product may not meet specifications for color description once reconstituted.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-264-2013 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2013-01-31 |
| Published | 2013-04-24 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Lupin Pharmaceuticals |
| Distribution | US |
Product
Suprax (cefixime for oral suspension) USP, 100 mg/5 mL, 50 mL bottles (when reconstituted), Manufactured for Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Baltimore, MD 21202, Manufactured by Lupin Limited Mumbai 400 058 India, NDC 68180-202-03.
Reason
Discoloration; Product may not meet specifications for color description once reconstituted.
Identifiers
| code_info | Lot #s: MSA 2021A, MSA 2024A, MSA 2025A, Exp July 2014 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-264-2013%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.